Jessica Murphy
Psychiatric/Mental Health · West Bend, WINPI 1831591270
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.4% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 10.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,496, more than ten times the $48 reported in 2023.
Across 145 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$325
- Vanda Pharmaceuticals Inc.$270
- Otsuka America Pharmaceutical, Inc.$263
- Johnson & Johnson$239
- Axsome Therapeutics, Inc.$232
- Teva Pharmaceuticals USA, Inc.$223
- plus $2K from 21 others
What the payments were for
- Food & beverage$2,92691%
- Education$2749%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 21 | $325 |
| Vanda Pharmaceuticals Inc. | 10 | $270 |
| Otsuka America Pharmaceutical, Inc. | 14 | $263 |
| Johnson & Johnson | 8 | $239 |
| Axsome Therapeutics, Inc. | 9 | $232 |
| Teva Pharmaceuticals USA, Inc. | 2 | $223 |
| AbbVie | 11 | $220 |
| Indivior Inc. | 7 | $198 |
| E.r. Squibb & Sons, L.L.C. | 8 | $174 |
| Collegium Pharmaceutical, Inc. | 10 | $173 |
| Neurocrine Biosciences, Inc. | 8 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $140 |
| Alkermes, Inc. | 4 | $105 |
| Sage Therapeutics, LLC | 5 | $98 |
| Supernus Pharmaceuticals, Inc. | 4 | $66 |
| Braeburn Inc. | 3 | $46 |
| Corium, LLC | 2 | $45 |
| Harmony Biosciences LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Novo Nordisk | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Amgen | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Orexo US, Inc. | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
| Livanova USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,200 in reported general payments places this provider in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $87,596 |
| OzempicSemaglutide | 21 | $30,946 |
| RybelsusSemaglutide | 12 | $29,140 |
| JardianceEmpagliflozin | 16 | $14,206 |
| FarxigaDapagliflozin Propanediol | 16 | $13,000 |
| XareltoRivaroxaban | 13 | $10,774 |
| MyrbetriqMirabegron | 14 | $8,838 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $3,468 |
| LantusInsulin Glargine,hum.Rec.Anlog | 13 | $3,407 |
| Atorvastatin Calcium | 280 | $3,144 |
| Omeprazole | 163 | $2,879 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,727 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,155 |
| Levothyroxine Sodium | 135 | $1,788 |
| Lisinopril | 169 | $1,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $22 | $60,08533 claims |
| Johnson & JohnsonXarelto | $239 | $10,77413 claims |
| AbbVieSynthroid | $220 | $1,34920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in West Bend
- Alyssa SekadloWest Bend$6K
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Bobbi DurstPewaukee$23K
- Ngozi ObioraMilwaukee$19K
- Glenda McConnellGreen Bay$14K
- Debra BenishekGreen Bay$12K
- Shalonda MylesBrown Deer$12K
- Victoria McGinleyMilwaukee$9K
- Janet BurnsBrookfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.